Efficacy and safety of miglustat in the treatment of GM2 gangliosidosis: A systematic review.
GM2 gangliosidosis
Sandhoff disease
Tay-Sachs disease
miglustat
substrate reduction therapy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
15
03
2023
received:
09
01
2023
accepted:
15
05
2023
medline:
8
8
2023
pubmed:
20
5
2023
entrez:
20
5
2023
Statut:
ppublish
Résumé
Since the results of previous studies regarding the safety and efficacy of miglustat in GM2 gangliosidosis (GM2g) were inconsistent, we aimed to assess miglustat therapy in GM2g patients. This study followed the latest version of PRISMA. We included the observational or interventional studies reporting GM2g patients under miglustat therapy by searching PubMed, Web of Science, and Scopus. Data extracted included the natural history of individual patient data, as well as the safety and efficacy of miglustat in GM2g patients. The quality assessment was performed using the Joanna Briggs Institute Critical Appraisal checklist. A total of 1023 records were identified and reduced to 621 after removing duplicates. After screening and applying the eligibility criteria, 10 articles and 2 abstracts met the inclusion criteria. Overall, the studies represented 54 patients with GM2g under treatment with miglustat and 22 patients with GM2g in the control group. Among patients with available data, 14 and 54 have been diagnosed with Sandhoff disease and Tay-Sachs disease, respectively. Patients included in this review consisted of 23 infantile, 4 late-infantile, 18 juvenile, and 31 adult-onset GM2g. Although miglustat should not be considered a definite treatment for GM2g, it appears that patients, particularly those with infantile or late-infantile GM2g, could benefit from miglustat therapy to some extent. We also make some suggestions regarding future studies presenting their findings in a standard format to facilitate pooling the available data in such rare diseases for a more comprehensive conclusion.
Sections du résumé
BACKGROUND
Since the results of previous studies regarding the safety and efficacy of miglustat in GM2 gangliosidosis (GM2g) were inconsistent, we aimed to assess miglustat therapy in GM2g patients.
METHODS
This study followed the latest version of PRISMA. We included the observational or interventional studies reporting GM2g patients under miglustat therapy by searching PubMed, Web of Science, and Scopus. Data extracted included the natural history of individual patient data, as well as the safety and efficacy of miglustat in GM2g patients. The quality assessment was performed using the Joanna Briggs Institute Critical Appraisal checklist.
RESULTS
A total of 1023 records were identified and reduced to 621 after removing duplicates. After screening and applying the eligibility criteria, 10 articles and 2 abstracts met the inclusion criteria. Overall, the studies represented 54 patients with GM2g under treatment with miglustat and 22 patients with GM2g in the control group. Among patients with available data, 14 and 54 have been diagnosed with Sandhoff disease and Tay-Sachs disease, respectively. Patients included in this review consisted of 23 infantile, 4 late-infantile, 18 juvenile, and 31 adult-onset GM2g.
CONCLUSIONS
Although miglustat should not be considered a definite treatment for GM2g, it appears that patients, particularly those with infantile or late-infantile GM2g, could benefit from miglustat therapy to some extent. We also make some suggestions regarding future studies presenting their findings in a standard format to facilitate pooling the available data in such rare diseases for a more comprehensive conclusion.
Substances chimiques
miglustat
ADN3S497AZ
1-Deoxynojirimycin
19130-96-2
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2919-2945Informations de copyright
© 2023 European Academy of Neurology.
Références
Kolter T, Sandhoff K. Sphingolipid metabolism diseases. Biochim Biophys Acta Biomembr. 2006;1758(12):2057-2079.
Maegawa GH, Stockley T, Tropak M, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics. 2006;118(5):e1550-e1562.
Jeyakumar M, Butters T, Dwek R, Platt F. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol. 2002;28(5):343-357.
Bley AE, Giannikopoulos OA, Hayden D, Kubilus K, Tifft CJ, Eichler FS. Natural history of infantile GM2 gangliosidosis. Pediatrics. 2011;128(5):e1233-e1241.
Cachon-Gonzalez MB, Zaccariotto E, Cox TM. Genetics and therapies for GM2 gangliosidosis. Curr Gene Ther. 2018;18(2):68-89.
Jacobs J, Willemsen M, Groot-Loonen J, Wevers R, Hoogerbrugge P. Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease. Bone Marrow Transplant. 2005;36(10):925-926.
Hoogerbrugge P, Brouwer O, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet. 1995;345(8962):1398-1402.
Norflus F, Tifft CJ, McDonald MP, et al. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest. 1998;101(9):1881-1888.
Arabi F, Mansouri V, Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother. 2022;153:113324. doi:10.1016/j.biopha.2022.113324
Flotte TR, Cataltepe O, Puri A, et al. AAV gene therapy for Tay-Sachs disease. Nat Med. 2022;28(2):251-259.
Lachmann RH, Platt FM. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Investig Drugs. 2001;10(3):455-466.
Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29(2-3):449-456.
Wraith JE, Imrie J. New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-887.
Chien Y, Peng S, Yang C, et al. Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis. 2013;36(1):129-137.
Patterson MC, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol. 2010;25(3):300-305.
Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269(11):8362-8365.
Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007;37(3):298-314.
Platt FM, Neises GR, Reinkensmeier G, et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997;276(5311):428-431.
Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A. 1999;96(11):6388-6393.
Bembi B, Marchetti F, Guerci V, et al. Substrate reduction therapy in the infantile form of Tay-Sachs disease. Neurology. 2006;66(2):278-280.
Villamizar-Schiller IT, Pabón LA, Hufnagel SB, et al. Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease. Eur J Med Genet. 2015;58(3):180-183.
Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med. 2009;11(6):425-433.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.
Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103-112.
Scherer RW, Saldanha IJ. How should systematic reviewers handle conference abstracts? A view from the trenches. Syst Rev. 2019;8(1):264. doi:10.1186/s13643-019-1188-0
NORD. Tay Sachs disease, subdivisions. 2022. Updated 2021. Accessed November 2022. https://rarediseases.org/rare-diseases/tay-sachs-disease/
Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds. Joanna Briggs Institute Reviewer's Manual. The Joanna Briggs Institute; 2017. https://synthesismanual.jbi.global
Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127-2133.
Tufanaru CMZ, Aromataris E, Campbell J, Hopp L. Chapter 3: Systematic reviews of effectiveness. In: Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. The Joanna Briggs Institute; 2020. https://synthesismanual.jbi.global
Jarnes Utz JR, Kim S, King K, et al. Infantile gangliosidoses: mapping a timeline of clinical changes. Mol Genet Metab. 2017;121(2):170-179.
King KE, Kim S, Whitley CB, Jarnes Utz JR. The juvenile gangliosidoses: a timeline of clinical change. Mol Genet Metab Rep. 2020;25:100676.
Maegawa GH, Banwell BL, Blaser S, et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Mol Genet Metab. 2009;98(1-2):215-224.
Masciullo M, Santoro M, Modoni A, et al. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J Inherit Metab Dis. 2010;33:355-361.
Tallaksen C, Berg J. Miglustat therapy in juvenile Sandhoff disease. J Inherit Metab Dis. 2009;32(1):289-293.
Wortmann S, Lefeber D, Dekomien G, Willemsen M, Wevers R, Morava E. Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab Dis. 2009;32(1):307-311.
Maegawa GH, van Giersbergen PL, Yang S, et al. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. Mol Genet Metab. 2009;97(4):284-291.
Clarke JTR, Maegawa GH, Banwell B, et al. Substrate reduction therapy with miglustat in juvenile GM2 gangliosidosis. Mol Genet Metab Rep. 2009;96:S18. doi:10.1016/j.ymgme.2008.11.028.
Maegawa G, Schmitt B, Blaser S, Banwell B, Hayes J, Clarke J. Brain MRS in patients with juvenile GM2 gangliosidosis receiving substrate reduction therapy. Mol Genet Metab. 2010;99(2):S26.
Tavasoli A, Hoseinpour S. Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD). 2022. Updated October 2022. Accessed November, 2022. https://clinicaltrials.gov/ct2/show/NCT03822013?cond=GM2+Gangliosidosis&cntry=IR&draw=2&rank=1
Paediatric Formulary Committee. British National Formulary for Children. British Medical Association and Royal Pharmaceutical Society of Great Britain. BMJ Publishing Group; 2005.
Zavesca (miglustat) full prescribing information. Actelion Pharmaceuticals US. November, 2022. Accessed September, 2022. https://www.zavesca.com/pdf/ZAVESCA-Full-Prescribing-Information.pdf
Gropman AL. Expanding the diagnostic and research toolbox for inborn errors of metabolism: the role of magnetic resonance spectroscopy. Mol Genet Metab. 2005;86(1-2):2-9. doi:10.1016/j.ymgme.2005.07.009
Leal AF, Benincore-Flórez E, Solano-Galarza D, et al. GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies. Int J Mol Sci. 2020;21(17):6213. doi:10.3390/ijms21176213
Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther. 2005;27(8):1215-1227. doi:10.1016/j.clinthera.2005.08.004
Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 2001;11(16):1283-1287. doi:10.1016/s0960-9822(01)00396-7
Elliot-Smith E, Speak AO, Lloyd-Evans E, et al. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab. 2008;94(2):204-211. doi:10.1016/j.ymgme.2008.02.005
Platt FM, Jeyakumar M, Andersson U, Heare T, Dwek RA, Butters TD. Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond Ser B Biol Sci. 2003;358(1433):947-954. doi:10.1098/rstb.2003.1279
Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2):441. doi:10.3390/ijms18020441
Lyseng-Williamson KAJD. Miglustat: a review of its use in Niemann-Pick disease type C. Orphanet J Rare Dis. 2014;74(1):61-74.
Belmatoug N, Burlina A, Giraldo P, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis. 2011;34(5):991-1001.
Amiri M, Naim HY. Long term differential consequences of miglustat therapy on intestinal disaccharidases. J Inherit Metab Dis. 2014;37(6):929-937.